On 19th July 2012, Fosun Pharma attended the closing ceremony and contract signing ceremony of The 4th Session Sino-African Entrepreneur Conference held in Beijing. Fosun Pharma entered into an investment project agreement in the ceremony for setting up FUSON-GUILIN PHARMA AFRIQUE FRANCOPHONE SARL in ABJ, Cote d'Ivoire. The new company will set foot in the whole Afrique Francophone area. Fosun's senior manager, Li Li-Gong, and Guilin Pharma's president, Yu Zhemin represented Fosun Pharma to attend the ceremony. 
  
It is reported that Fosun Pharma's investment project is the only pharmaceutical project among 9 projects concluded in this Sino-African Forum. The new subsidiary will become a high-tech pharmaceutical company producing the Artesun series products. It will develop the market of Artesunate series compound oral agents so as to drive the common medicine product sales in the whole Afrique Francophone pharmaceutical market. Furthermore, the new subsidiary plans to develop and set up the production line of anti-infective agents. Its business will cover 17 French-spoken areas, including Cote d'Ivoire, Senegal, Cameroon, Gabon, Niger, Chad, Congo (Kinshasa), Congo (Brazzaville), Mauritania, Burkina Faso, Benin, Togo, Burundi, Madagascar, Mali, Guinea, Central Africa, etc. It will lay a solid foundation for Fosun Pharma to develop the long-term business in the west African countries.

Fosun Pharma devotes to the modern biological medicine health industry. Meanwhile Fosun Pharma found and grasped the big opportunity under the circumstances that the pharmaceutical market rapid grew up domestically and Chinese pharmaceutical enterprise extended the business to the world mainstream pharmaceutical market. It made Fosun Pharma strategically set up various critical links covering the R&D, manufacture, distribution, and final sales, etc. Fosun Pharma takes the pharmaceutical R&D as the core. Meanwhile, it also leads the pharmaceutical market in such fields as pharmaceutical circulation, medical service, medical diagnosis, and medical equipment, etc. Besides the pharmaceutical research and manufacture, Fosun Pharma also excels at its management, including the technical innovation, marketing, business integration, and talent cultivation, etc. Taking the above advantages, Fosun Pharma becomes a large group to specialize in the pharmaceutical health industry. Guilin Pharma (holding) Corporation is Fosun's member enterprise. It is the largest antimalarial medicine manufacture in the world. It is also the only Chinese pharmaceutical enterprise which is pre-qualified by WHO regarding its oral agents and injection product. Of these products, the Artesun used for the injection is pre-qualified by WHO in November 2010. It is strongly recommended by WHO in Malaria Treatment Guidelines to be the first choice for the adult and child severe malaria treatment. And so far, it is still the only anti-malaria medicine complying with the international quality standard. For the purpose of developing the African pharmaceutical market, Guilin Pharma set up 4 offices in Myanmar, Nigeria, Kenya, and Uganda. It also set up the wholly-owned subsidiary in Ghana. Through these efforts, a sales network has been basically established covering malaria high-risk areas among the English-spoken countries. Fosun has become one of domestic pharmaceutical enterprises firstly extending the business to the overseas market, relying upon good reputation of its anti-malaria medicine in the world.